Abstract
Background: Tuberculosis (TB) ranks alongside the human immunodeficiency virus (HIV) as cause of death due to an infectious disease. Recently, host-targeted therapies (HDT) have gained attention as a means to shorten the course of treatment of drug-sensitive TB, improve treatment outcomes of drug-resistant TB and generally improve the efficacy and preserve or restore lung architecture of TB patients. It has been suggested that supplementing anti-TB therapy with host response modulators will augment standard TB treatment by overcoming antibiotic resistance in pathogenic strains of Mycobacterium tuberculosis (Mtb) and related species, thus aiding in killing non-replicating bacilli. Methods: The aim of this review is to examine pulmonary delivery strategies that can enhance the safety as well as efficacy of HDT against pulmonary TB. We reviewed literature in the public domain and revisited our own results on inhaled HDT to arrive at broad conclusions. Results: HDT can be viewed as a strategy to evoke one or more of the following macrophage responses: (i) soluble, intracellular factors such as free radicals and antimicrobial peptides; (ii) soluble extracellular signals like cytokines, chemokines, prostaglandins, lipids, etc.; (iii) organelles and assemblies such as phagolysosomes or the inflammasome; (iv) Autophagy, via mTOR/S6 Kinase; and (v) apoptosis via caspases, bcr/abl products, etc. All of these may be optimally addressed using drugs approved for other uses. Conclusion: Deployment of HDT in TB may be optimally achieved through macrophage-targeted inhaled delivery systems.
Keywords: Macrophage, inhalation, pulmonary drug delivery, nitric oxide, cytokines, apoptosis, autophagy.
Current Pharmaceutical Design
Title:Opportunities and Challenges for Host-Directed Therapies in Tuberculosis
Volume: 22 Issue: 17
Author(s): Madhur Sachan, Ashish Srivastava, Rajeev Ranjan, Anuradha Gupta, Sanketkumar Pandya and Amit Misra
Affiliation:
Keywords: Macrophage, inhalation, pulmonary drug delivery, nitric oxide, cytokines, apoptosis, autophagy.
Abstract: Background: Tuberculosis (TB) ranks alongside the human immunodeficiency virus (HIV) as cause of death due to an infectious disease. Recently, host-targeted therapies (HDT) have gained attention as a means to shorten the course of treatment of drug-sensitive TB, improve treatment outcomes of drug-resistant TB and generally improve the efficacy and preserve or restore lung architecture of TB patients. It has been suggested that supplementing anti-TB therapy with host response modulators will augment standard TB treatment by overcoming antibiotic resistance in pathogenic strains of Mycobacterium tuberculosis (Mtb) and related species, thus aiding in killing non-replicating bacilli. Methods: The aim of this review is to examine pulmonary delivery strategies that can enhance the safety as well as efficacy of HDT against pulmonary TB. We reviewed literature in the public domain and revisited our own results on inhaled HDT to arrive at broad conclusions. Results: HDT can be viewed as a strategy to evoke one or more of the following macrophage responses: (i) soluble, intracellular factors such as free radicals and antimicrobial peptides; (ii) soluble extracellular signals like cytokines, chemokines, prostaglandins, lipids, etc.; (iii) organelles and assemblies such as phagolysosomes or the inflammasome; (iv) Autophagy, via mTOR/S6 Kinase; and (v) apoptosis via caspases, bcr/abl products, etc. All of these may be optimally addressed using drugs approved for other uses. Conclusion: Deployment of HDT in TB may be optimally achieved through macrophage-targeted inhaled delivery systems.
Export Options
About this article
Cite this article as:
Sachan Madhur, Srivastava Ashish, Ranjan Rajeev, Gupta Anuradha, Pandya Sanketkumar and Misra Amit, Opportunities and Challenges for Host-Directed Therapies in Tuberculosis, Current Pharmaceutical Design 2016; 22 (17) . https://dx.doi.org/10.2174/1381612822666160128150636
DOI https://dx.doi.org/10.2174/1381612822666160128150636 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in the Development of Small-Molecular Inhibitors Target HIV Integrase-LEDGF/p75 Interaction
Mini-Reviews in Medicinal Chemistry The Immune-Endocrine-Metabolic Unit During Human Tuberculosis
Current Immunology Reviews (Discontinued) Design, Synthesis and Docking Study of Some Novel Isatin- Quinoline Hybrids as Potential Antitubercular Agents
Anti-Infective Agents New Perspectives of Infections in Cardiovascular Disease
Current Cardiology Reviews Angiopoietin-1 and C16 Peptide Attenuate Vascular and Inflammatory Responses in Experimental Allergic Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Regulation of Protective and Pathogenic Th17 Responses
Current Immunology Reviews (Discontinued) Electronic Noses in Medical Diagnostics
Current Medicinal Chemistry The Past, Present and Future Subclassification of Patients with Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Essential Oils with Microbicidal and Antibiofilm Activity
Current Pharmaceutical Biotechnology Assessing the Performance of 3D Pharmacophore Models in Virtual Screening: How Good are They?
Current Topics in Medicinal Chemistry The Yin and Yang of Inflammation
Current Molecular Medicine Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry Formulation and Evaluation of Isoniazid Loaded Nanosponges for Topical Delivery
Pharmaceutical Nanotechnology Review of Current Chemoinformatic Tools for Modeling Important Aspects of CYPsmediated Drug Metabolism. Integrating Metabolism Data with Other Biological Profiles to Enhance Drug Discovery
Current Drug Metabolism Progress of Biological Agents on Psoriatic Arthritis
Current Pharmaceutical Biotechnology Transcription Factors in Autoimmune Diseases
Current Pharmaceutical Design Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents
Infectious Disorders - Drug Targets Endophytic Fungi in the Fight Against Neglected Tropical Diseases
Mini-Reviews in Medicinal Chemistry Proteomics for Transthyretin (TTR) Related Amyloidosis
Current Proteomics Antimycotic Drugs and their Mechanisms of Resistance to <i>Candida</i> Species
Current Drug Targets